Ensysce Biosciences, Inc.
ENSC
$0.25
$0.000.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 281.73% | -64.04% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 281.73% | -64.04% | |||
| Cost of Revenue | 22.27% | 53.63% | |||
| Gross Profit | 29.70% | -345.98% | |||
| SG&A Expenses | -17.84% | 6.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.16% | 35.62% | |||
| Operating Income | 25.64% | -113.72% | |||
| Income Before Tax | 25.77% | -115.12% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.77% | -115.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.78% | -115.13% | |||
| EBIT | 25.64% | -113.72% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 41.95% | -64.16% | |||
| Normalized Basic EPS | 41.96% | -64.18% | |||
| EPS Diluted | 41.95% | -64.16% | |||
| Normalized Diluted EPS | 41.96% | -64.18% | |||
| Average Basic Shares Outstanding | 27.86% | 31.05% | |||
| Average Diluted Shares Outstanding | 27.86% | 31.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||